Published in Circulation on July 27, 1999
Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med (2001) 1.75
PKCalpha regulates platelet granule secretion and thrombus formation in mice. J Clin Invest (2009) 1.41
Integrin targeted therapeutics. Theranostics (2011) 1.36
Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT. Theranostics (2011) 1.25
Future innovations in anti-platelet therapies. Br J Pharmacol (2008) 1.13
Clinical review: Traumatic brain injury in patients receiving antiplatelet medication. Crit Care (2012) 0.94
The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy. Perspect Medicin Chem (2008) 0.91
Review of Currently Available GP IIb/IIIa Inhibitors and Their Role in Peripheral Vascular Interventions. Semin Intervent Radiol (2010) 0.87
Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: A review. Exp Clin Cardiol (2008) 0.84
The platelet fibrinogen receptor: from megakaryocyte to the mortuary. JRSM Cardiovasc Dis (2012) 0.83
Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial. Neth Heart J (2007) 0.81
Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor. Mol Ther (2011) 0.77
Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. Arterioscler Thromb Vasc Biol (2016) 0.76
Use of antiplatelet inhibitors in peripheral vascular interventions. Semin Intervent Radiol (2005) 0.75
Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons? J Interv Cardiol (2013) 0.75
RP-HPLC Method Development and Validation for Determination of Eptifibatide Acetate in Bulk Drug Substance and Pharmaceutical Dosage Forms. Iran J Pharm Res (2017) 0.75
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med (1996) 5.94
Exposed protein on the intact human erythrocyte. Biochemistry (1971) 4.56
Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone. Identity with platelet glycoprotein IIIa and similarity to "integrin". J Biol Chem (1987) 3.87
The arrangement of proteins in the human erythrocyte membrane. Biochem Biophys Res Commun (1970) 3.54
Pregnant teenagers' knowledge and use of emergency contraception. BMJ (1995) 3.51
Platelet plasma membrane glycoproteins. Evidence for the presence of nonequivalent disulfide bonds using nonreduced-reduced two-dimensional gel electrophoresis. J Biol Chem (1977) 3.19
Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. Nature (1999) 2.71
Identification of membrane proteins mediating the interaction of human platelets. J Cell Biol (1980) 2.65
The formation of cis-3-nonenal, trans-2-nonenal and hexanal from linoleic acid hydroperoxide isomers by a hydroperoxide cleavage enzyme system in cucumber (Cucumis sativus) fruits. Biochim Biophys Acta (1976) 2.48
Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J Clin Invest (1977) 2.43
Effect of trypsin on the exposed polypeptides and glycoproteins in the human platelet membrane. Biochemistry (1972) 2.41
Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation (1998) 2.37
Platelet glycoproteins IIb and IIIa: evidence for a family of immunologically and structurally related glycoproteins in mammalian cells. Proc Natl Acad Sci U S A (1986) 2.30
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet (2001) 2.23
Myonecrosis after revascularization procedures. J Am Coll Cardiol (1998) 2.11
Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb-III complex. J Biol Chem (1982) 2.10
Ca2+-mediated association of glycoprotein G (thrombinsensitive protein, thrombospondin) with human platelets. J Biol Chem (1980) 2.08
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. Eur Heart J (2002) 2.06
Dobutamine echocardiography in myocardial hibernation. Optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. Circulation (1995) 2.04
Biochemical studies of two patients with the gray platelet syndrome. Selective deficiency of platelet alpha granules. J Clin Invest (1980) 2.01
Human and bovine endothelial cells synthesize membrane proteins similar to human platelet glycoproteins IIb and IIIa. J Biol Chem (1985) 2.00
Ca2+-dependent protease in human platelets. Specific cleavage of platelet polypeptides in the presence of added Ca2+. J Biol Chem (1977) 1.99
Comparison of cDNA-derived protein sequences of the human fibronectin and vitronectin receptor alpha-subunits and platelet glycoprotein IIb. Biochemistry (1987) 1.99
Inhibition of actin polymerization in blood platelets by cytochalasins. Nature (1981) 1.92
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation (1996) 1.87
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation (2001) 1.83
Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation (1999) 1.83
Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation (2000) 1.79
Molecular defects in interactions of platelets with the vessel wall. N Engl J Med (1984) 1.78
Calcium-dependent proteolysis occurs during platelet aggregation. J Biol Chem (1983) 1.74
Outside-in integrin signal transduction. Alpha IIb beta 3-(GP IIb IIIa) tyrosine phosphorylation induced by platelet aggregation. J Biol Chem (1996) 1.70
Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand's disease. J Clin Invest (1976) 1.67
Platelet glycoprotein IIb-IIIa-like proteins mediate endothelial cell attachment to adhesive proteins and the extracellular matrix. J Biol Chem (1987) 1.65
Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study. Circulation (1998) 1.62
Identification of two proteins (actin-binding protein and P235) that are hydrolyzed by endogenous Ca2+-dependent protease during platelet aggregation. J Biol Chem (1985) 1.59
Changes in the cytoskeletal structure of human platelets following thrombin activation. J Biol Chem (1981) 1.58
Calcium regulation of the platelet membrane glycoprotein IIb-IIIa complex. J Biol Chem (1985) 1.56
Thrombin-induced platelet aggregation is mediated by a platelet plasma membrane-bound lectin. Science (1978) 1.55
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med (1999) 1.55
Earlier diagnosis and treatment of acute myocardial infarction necessitates the need for a 'new diagnostic mind-set'. Circulation (1994) 1.53
Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem (1993) 1.53
Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem (1993) 1.53
Atopic eczema and the home environment. Br J Dermatol (2001) 1.52
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J (2002) 1.50
Lipoxygenase from potato tubers. Partial purification and properties of an enzyme that specifically oxygenates the 9-position of linoleic acid. Biochem J (1971) 1.49
Visualization of ventricular fibroelastoma with a video-assisted thoracoscope. Ann Thorac Surg (1997) 1.49
The platelet fibrinogen receptor: an immunogold-surface replica study of agonist-induced ligand binding and receptor clustering. J Cell Biol (1987) 1.47
Structure of human platelet membrane glycoproteins IIb and IIIa as determined by electron microscopy. J Biol Chem (1985) 1.47
Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. Am J Cardiol (1994) 1.45
Role of phosphorylation in mediating the association of myosin with the cytoskeletal structures of human platelets. J Biol Chem (1982) 1.44
Spectrin is associated with membrane-bound actin filaments in platelets and is hydrolyzed by the Ca2+-dependent protease during platelet activation. Blood (1987) 1.43
Platelet membrane glycoproteins: functions in cellular interactions. Annu Rev Cell Biol (1990) 1.42
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J Thromb Haemost (2005) 1.42
Use of bare-mounted Palmaz-Schatz stents employing the stent saddle technique on the delivery balloon: a single center experience. Cathet Cardiovasc Diagn (1997) 1.39
Policy issues in the private health sector: examples from long-term care in the U.K. Soc Sci Med (1996) 1.36
Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem (1991) 1.36
Genetic and pharmacological analyses of Syk function in alphaIIbbeta3 signaling in platelets. Blood (1999) 1.35
Teenage pregnancy: a comparative study of teenagers choosing termination of pregnancy or antenatal care. J R Soc Med (1995) 1.35
Tyrosine phosphorylation of the beta3 cytoplasmic domain mediates integrin-cytoskeletal interactions. J Biol Chem (1998) 1.34
A method for purifying the platelet membrane glycoprotein IIb-IIIa complex. Anal Biochem (1985) 1.30
Actin filament content and organization in unstimulated platelets. J Cell Biol (1984) 1.28
Another source of cellulase. Nature (1969) 1.26
Identification of shc as the primary protein binding to the tyrosine-phosphorylated beta 3 subunit of alpha IIbbeta 3 during outside-in integrin platelet signaling. J Biol Chem (2000) 1.25
Purification and preliminary physicochemical characterization of human platelet membrane glycoprotein V. J Biol Chem (1981) 1.24
Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide. J Biol Chem (1991) 1.22
Reconstitution of the purified platelet fibrinogen receptor. Fibrinogen binding properties of the glycoprotein IIb-IIIa complex. J Biol Chem (1985) 1.22
Platelet membrane glycoprotein IIb-IIIa complex incorporated into phospholipid vesicles. Preparation and morphology. J Biol Chem (1985) 1.19
Organization of the cytoskeleton in resting, discoid platelets: preservation of actin filaments by a modified fixation that prevents osmium damage. J Cell Biol (1985) 1.16
Polymerization and organization of actin filaments within platelets. Semin Hematol (1983) 1.16
Synthetic peptides derived from fibrinogen and fibronectin change the conformation of purified platelet glycoprotein IIb-IIIa. J Biol Chem (1987) 1.16
Characterization of covalent adriamycin-DNA adducts. Proc Natl Acad Sci U S A (1998) 1.16
Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation (1994) 1.15
Thrombin substrates and the proteolytic site of thrombin action on human-platelet plasma membranes. Biochim Biophys Acta (1974) 1.15
Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. Nature (1975) 1.13
Platelet plasma membrane glycoproteins. Identification of a proteolytic substrate for thrombin. Biochem Biophys Res Commun (1977) 1.13
Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost (2007) 1.13
Prinzmetal's angina during 5-fluorouracil chemotherapy. Am J Med (1987) 1.12
The enzymic conversion of linoleic acid into 9-(nona-1',3'-dienoxy)non-8-enoic acid, a novel unsaturated ether derivative isolated from homogenates of Solanum tuberosum tubers. Biochem J (1972) 1.12
cDNA cloning and expression of platelet p24/CD9. Evidence for a new family of multiple membrane-spanning proteins. J Biol Chem (1991) 1.11
An evaluation of membrane glycoproteins in platelet adhesion and aggregation. Prog Hemost Thromb (1980) 1.10
Fibrinogen binding to human platelet plasma membranes. Identification of two steps requiring divalent cations. J Biol Chem (1983) 1.10
Adhesive properties of the beta 3 integrins: comparison of GP IIb-IIIa and the vitronectin receptor individually expressed in human melanoma cells. J Cell Biol (1991) 1.07
Calcium cation regulation of glycoprotein IIb-IIIa complex formation in platelet plasma membranes. J Biol Chem (1983) 1.07
Platelet plasma membrane lectin activity. Biochem Biophys Res Commun (1977) 1.07
Fibronectin-binding properties of the purified platelet glycoprotein IIb-IIIa complex. J Biol Chem (1986) 1.07
Aging trends--Singapore. J Cross Cult Gerontol (1995) 1.07
Increased thrombin responsiveness in platelets from mice lacking glycoprotein V. Proc Natl Acad Sci U S A (1999) 1.06
Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol (1995) 1.06
Estimation of left ventricular end-diastolic pressure from Doppler transmitral flow velocity in cardiac patients independent of systolic performance. J Am Coll Cardiol (1992) 1.05
Effectiveness of manipulative physiotherapy for the treatment of a neurogenic cervicobrachial pain syndrome: a single case study -- experimental design. Man Ther (2002) 1.05
alpha-Actinin deficiency in thrombasthenia: possible identity of alpha-actinin and glycoprotein III. Am J Pathol (1979) 1.05
Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease. J Investig Med (1995) 1.05
Atopic eczema and domestic water hardness. Lancet (1998) 1.04
Kinetics and sequence specificity of drug-DNA interactions: an in vitro transcription assay. Biochemistry (1986) 1.04
Spatial variations in attendance at general practitioner services. Soc Sci Med (1979) 1.04
Subcellular localization of porphyrins using confocal laser scanning microscopy. Photochem Photobiol (1991) 1.04